Iran Pharmaceuticals and Healthcare Report Q2

Executive Summary .........5
SWOT Analysis ....................... 7
Table: Iran Pharmaceuticals And Healthcare Industry SWOT. 7
Iran Political SWOT ............. 8
Iran Economic SWOT........... 8
Iran Business Environment SWOT.................. 9
Business Environment Ranking ...........10
Table: Middle East And Africa Pharmaceutical Business Environment Ratings Q209............. 10
Limits Of Potential Returns .......................... 10
Risks To Realisation Of Returns ................... 11
Market Summary ............12
Registration Of Imports ...... 14
Generic Registration........... 14
Intellectual Property (IP) Regime................. 15
Intellectual Property Disputes ...................... 15
Counterfeit Medicines......... 16
Pricing And Reimbursement ......................... 17
Recent Pricing And Reimbursement Developments ................ 17
Industry Developments..19
Epidemiology...................... 19
HIV/AIDS Situation ............ 20
Table: Iran HIV/AIDS Prevalence................ 21
Healthcare Sector ............... 21
Primary Care...................... 22
Secondary Care .................. 23
Health Insurance ................ 23
Regional Developments ...... 24
International Healthcare Collaboration ....... 25
Pharmaceutical Industry..... 25
Pharmaceutical Industry Recent Developments...................... 27
Traditional Herbal Remedies........................ 27
Recent Company Activity .... 28
Retail Pharmacies............... 29
Research And Development .......................... 29
International Pharmaceutical Collaboration.......................... 30
Industry Forecast Scenario ...................32
Overall Drug Market Forecast ..................... 32
Table: Iran – Drug Expenditure Forecasts, 2003-2013 (IRRmn unless otherwise stated) ........ 33
Industry Growth Factors .... 34
Table: Iran – Health Expenditure Forecasts, 2003-2013 (IRRmn unless otherwise stated)...... 35
Macroeconomic Growth Factors .................. 36
Table: Iran – Economic Activity ................... 39
Prescription Drug Market Forecast.............. 40
Table: Iran – Prescription Drug Market Forecast, 2003-2013 (US$mn unless otherwise stated) ...................... 41
OTC Drug Market Forecast.......................... 42
Table: Iran – OTC Market Data Forecasts, 2003-2013 (US$mn unless otherwise stated) ....... 43
Patented Drug Market Forecast ................... 44
Table: Iran – Patented Market Forecasts, 2003-2013 (IRRmn unless otherwise stated) .......... 45
Generic Drug Market Forecast..................... 46
Table: Iran – Generics Market Forecasts, 2003-2013 (IRRmn unless otherwise stated) .......... 46
Medical Device Market Forecast.................. 47
Table: Iran – Medical Device Market Forecast, 2006-2013 (US$mn unless otherwise stated) .......................... 49
Import/Export Market Forecast .................... 50
Table: Iran – Pharmaceutical Trade Indicators, 2003-2013 (US$mn) ........... 51
Other Healthcare Data Forecasts................. 52
Table: Iran – Other Health Indicators, 2003-2013................. 52
Key Risks To BMI’s Forecast Scenario......... 52
Competitive Landscape.54
Company Profiles...........55
Multinationals....................... 55
Novartis .... 55
Merck & Co ........................ 55
Pfizer ........ 55
GlaxoSmithKline................. 55
Sanofi-Aventis..................... 55
Indigenous Companies.......... 56
Darou Pakhsh..................... 56
Caspian Tamin Pharmaceutical Company*.. 58
Pharmieco .......................... 60
Pars Darou ......................... 61
Zahravi ..... 63
Amin ......... 65
Sina Darou Pharmaceutical Company ......... 66
Exir Pharmaceuticals ......... 68
Country Snapshot: Iran Demographic Data ..................69
Section 1: Population.......... 69
Table: Demographic Indicators, 2005-2030. 69
Table: Rural/Urban Breakdown, 2005-2030 .......................... 70
Section 2: Education And Healthcare........... 70
Table: Education, 2002-2005 ....................... 70
Table: Vital Statistics, 2005-2030................. 70
Section 3: Labour Market And Spending Power ..................... 71
Table: Employment Indicators, 1996-2005... 71
Table: Consumer Expenditure, 2000-2012 (US$)................... 72
Table: Average Annual Manufacturing Wages, 2000-2012 .... 72
BMI Forecast Modelling.73
How We Generate Our Pharmaceutical Industry Forecasts ..... 73
Pharmaceutical Business Environment Ratings Methodology .. 74
Ratings Overview................ 74
Table: Pharmaceutical Business Environment Indicators ...... 74
Weighting............................ 76
Table: Weighting Of Components................. 76